All News

The margins may be lower, but skirting access and reimbursement issues in an increasingly skeptical payer environment makes over-the-counter (OTC) products appealing to certain big players.

Global Launch in the Post-Blockbuster Era

Today’s big product story - the apparent end to a decade-long drought in the drug development pipeline - is the prep stage for tomorrow’s big policy question: are industry R&D priorities in synch with the changing burden of disease?

The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer.

Forest Labs has had a tough time with regulators over the last two years. The company’s sales reps can’t seem to stop breaking the law.

Can’t get your sales rep into that academic medical center? Try sending a medical science liaison (MSL).

Piramal Pivots for Growth

This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances

As a drug company promoting a drug free Olympiad, GSK wins our gold hands down for finally putting the industry's best face forward on the last frontier of advertising-the TV sets of Europe.

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS

The decisions you make today about patents – what, when and where to file – could have implications tantamount to billions of dollars in R&D investment and sales over the next two decades.

In April 2012, industry experts discussed the issue of atypical visible particles in pharmaceutical raw materials, including excipients, at the joint International Pharmaceutical Excipient Council’s (IPEC) Regulatory Conference and ExcipientFest-Americas Conference in San Juan, Puerto Rico

Patient groups are a growing force, not just in the debate around tactical areas of medical specialities, but also on the vital question of pricing and reimbursement rules. But will their voices be heard? Reflector reports.

Video created by Topin fore Pharmaceutical Executive

Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. But is it working? Andrea Sobrio reports.

It’s an unusual sight in the UK - a television commercial for a Big Pharma company. But among the cultural and commercial innovations being attributed to the London Olympic Games is GSK’s first UK consumer-facing corporate brand campaign, showcasing its anti-doping operations.

At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.

Like governors in the US vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns.

The European Commission has followed the UK government’s plans to make all publicly funded scientific research available for free, announcing that it will improve access to scientific information in Europe.

The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?

It may surprise some working in the industry, but pharmaceutical companies, in particular those in Europe, rank among the world’s best online corporate communicators, writes David Bowen.

Last month, Pharm Exec, the Tufts Center for the Study of Drug Development and software vendor Clear Trial brought companies together for an editorial exchange on current challenges in budgeting and spend for clinical trials.

Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy).

EFPIA president Andrew Witty is hoping that the deepening European economic crisis will impel European leaders towards more courageous and radical solutions, writes Reflector.

2012 Emerging Pharma Leaders

Pharm Exec's 2012 roster of Emerging Leaders-our sixth to date-is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.

If you’re like me, you probably bounded out of bed on Thursday morning, took in all the news you could find about the Supreme Court and healthcare reform…and then you waited.

Examples of the various video formats that can now be offered from Advanstar Pharma Science Multimedia

Patients who live for many years following a cancer diagnosis will likely require additional support, and a whole new kind of follow-up care.